Can I read The Potential of Antibody‐based Immunosuppressive Agents for Corneal Transplantation on EtoBox?

The Potential of Antibody‐based Immunosuppressive Agents for Corneal Transplantation by Michael A Thiel; Douglas J Coster; Keryn A Williams is a Immunology and Microbiology article available to read on EtoBox.

What is The Potential of Antibody‐based Immunosuppressive Agents for Corneal Transplantation about?

Corneal transplantation is a sight‐restorative procedure but its success is limited by irreversible graft rejection, which accounts for up to 50 per cent of failures. The normal eye is an immune‐privileged site. Multiple mechanisms maintain ocular privilege, including the blood–eye barrier, the lack of blood vessels and lymphatics in the normal cornea, the relative paucity of mature antigen‐presenting cells in the central cornea, the presence of immunomodulatory factors in ocular fluids, and the constitutive expressive of CD95L (Fas ligand) within the eye. However, privilege can be eroded by the sequelae of inflammation and neovascularization. Corneal graft rejection in humans is currently suppressed with topical glucocorticosteroids, which are moderately effective. Systemically administered immunosuppressive therapy is of limited efficacy and may be accompanied by unacceptable morbidity. Alternative therapies are needed to improve outcomes. Corneal graft rejection is primarily a cell‐mediated response controlled by the CD4^+^ T cell, and thus CD4 and costimulatory molecule blockade are appealing targets for new therapeutic interventions. A number of monoclonal antibodies have show

Who reads The Potential of Antibody‐based Immunosuppressive Agents for Corneal Transplantation?

Author

Michael A Thiel; Douglas J Coster; Keryn A Williams

Publisher

Nature Publishing Group; Wiley (Blackwell Publishing); John Wiley and Sons Inc.; Wiley (ISSN 0818-9641)

Published

2003

Language

EN

Field

Immunology and Microbiology (Life Sciences)